Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that ...

Eli Lilly and Company LLY will report first-quarter ... growth drugs (select products launched prior to 2022 like Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and ...

Eli Lilly and Company LLY will report its fourth ... Higher demand and volume growth for Lilly’s key growth drugs like Emgality, Olumiant, Retevmo, Taltz and Verzenio are likely to have provided ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

Eli Lilly & Co. Says Head-to-Head Clinical Trial Reaffirms Efficacy of Emgality in Episodic Migraine Prevention, Study Misses Primary Endpoint Eli Lilly and Company (NYSE:LLY) announced results of ...